Literature DB >> 10527089

Oxygen uptake during peak graded exercise and single-stage fatigue tests of wheelchair propulsion in manual wheelchair users and the able-bodied.

R E Keyser1, M M Rodgers, E R Gardner, P J Russell.   

Abstract

OBJECTIVE: To determine if a single-stage, submaximal fatigue test on a wheelchair ergometer would result in higher than expected energy expenditure.
DESIGN: An experimental survey design contrasting physiologic responses during peak graded exercise tests and fatigue tests.
SETTING: A rehabilitation science laboratory that included a prototypical wheelchair ergometer, open-circuit spirometry system, and heart rate monitor. PARTICIPANTS: Nine able-bodied non-wheelchair users (the NWC group: 6 men and 3 women, mean +/- SD age 30 +/- 7yrs) and 15 manual wheelchair users (the WC group: 12 men and 3 women, age 40 +/- 9yrs, time in wheelchair 16 +/- 9yrs). No subject had any disease, medication regimen, or upper body neurologic, orthopedic, or other condition that would limit wheelchair exercise. MAIN OUTCOME MEASURES: Peak oxygen uptake (VO2) for graded exercise testing and during fatigue testing, using a power output corresponding to 75% peak aerobic capacity on graded exercise test.
RESULTS: In the WC group, VO2 at 6 minutes of fatigue testing was not significantly different from peak VO2. In the NWC group, VO2 was similar to the expected level throughout fatigue testing.
CONCLUSION: Energy expenditure was higher than expected in the WC group but not in the NWC group. Fatigue testing may provide a useful evaluation of cardiorespiratory status in manual wheelchair users.

Entities:  

Mesh:

Year:  1999        PMID: 10527089     DOI: 10.1016/s0003-9993(99)90031-x

Source DB:  PubMed          Journal:  Arch Phys Med Rehabil        ISSN: 0003-9993            Impact factor:   3.966


  1 in total

1.  Physiological adaptations to exercise in people with spinal cord injury.

Authors:  J Vidal; C Javierre; R Segura; A Lizarraga; J R Barbany; A Pérez
Journal:  J Physiol Biochem       Date:  2003-03       Impact factor: 4.158

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.